Teva Plans To Take Skinny-Label Defeat To Supreme Court
Company Confirms It Will Seek Review Of GSK Labeling Carve-Outs Litigation In US
Following the decision by the US Court of Appeals for the Federal Circuit not to rehear “en banc” Teva’s litigation with GSK revolving around skinny-label generic carvedilol, the Israeli company has confirmed that it will seek Supreme Court review of the ruling.
